Literature DB >> 27464969

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.

Vipul Pareek1, Mary Welch1, Elizabeth Ravera1, Richard L Zampolin2, Lecia V Sequist3, Balazs Halmos4.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27464969     DOI： 10.1016/j.jtho.2016.07.010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.

Authors:  Manmeet S Ahluwalia; Kevin Becker; Benjamin P Levy
Journal:  Oncologist       Date:  2018-04-12

2.  Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.

Authors:  Takehiro Uemura; Tetsuya Oguri; Minami Okayama; Hiromi Furuta; Yoshihiro Kanemitsu; Osamu Takakuwa; Hirotsugu Ohkubo; Masaya Takemura; Ken Maeno; Yutaka Ito; Akio Niimi
Journal:  Mol Clin Oncol       Date:  2017-03-03

3.  Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Authors:  James C H Yang; Sang-We Kim; Dong-Wan Kim; Jong-Seok Lee; Byoung Chul Cho; Jin-Seok Ahn; Dae H Lee; Tae Min Kim; Jonathan W Goldman; Ronald B Natale; Andrew P Brown; Barbara Collins; Juliann Chmielecki; Karthick Vishwanathan; Ariadna Mendoza-Naranjo; Myung-Ju Ahn
Journal:  J Clin Oncol       Date:  2019-12-06       Impact factor: 44.544

4.  Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.

Authors:  Xiao-Fang Yi; Jun Song; Ruo-Lin Gao; Li Sun; Zhi-Xuan Wu; Shu-Ling Zhang; Le-Tian Huang; Jie-Tao Ma; Cheng-Bo Han
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

5.  Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Authors:  Shigeki Nanjo; Akito Hata; Chiyuki Okuda; Reiko Kaji; Hideaki Okada; Daisuke Tamura; Kei Irie; Hiroshi Okada; Shoji Fukushima; Nobuyuki Katakami
Journal:  Br J Cancer       Date:  2017-11-30       Impact factor: 7.640

Review 6.  Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Authors:  Mariacarmela Santarpia; Alessia Liguori; Niki Karachaliou; Maria Gonzalez-Cao; Maria Grazia Daffinà; Alessandro D'Aveni; Grazia Marabello; Giuseppe Altavilla; Rafael Rosell
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18

7.  Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.

Authors:  Yung-Hsuan Chen; Yen-Fu Chen; Chung-Yu Chen; Jin-Yuan Shih; Chong-Jen Yu
Journal:  BMC Cancer       Date:  2019-10-26       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.